Shire’s Replagal Withdrawn: A “Non-Traditional” Review Ends Badly

Shire’s decision to take its Fabry Disease therapy and go home sets up two possible narratives. One accentuates FDA’s apparent inflexibility and is sure to reinforce calls for legislative changes to the approval standard. The other highlights a recalcitrant or even petulant-sounding sponsor. Neither is likely to sound good to Fabry’s patients.

More from US FDA Performance Tracker

More from Regulatory Trackers